Fred Lublin - Concepedia

Author

Fred Lublin

Icahn School of Medicine at Mount Sinai ORCID

Also Known As

A. Miller, E. Havrdova, Eva Havrdova, F D Lublin, F Lublin, F. D. Lublin, F. Lublin, F.D Lublin, F.D. LUBLIN, F.D. Lublin

431

Publications

64.4K

Citations

H-Index

180

Concepts

All Affiliations

Icahn School of Medicine at Mount Sinai The University of Texas Health Science Center at Houston University of Alabama at Birmingham University Hospital of Basel Thomas Jefferson University

About

Fred Lublin is an author at Icahn School of Medicine at Mount Sinai specializing in medicine, neurology, and multiple sclerosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	54	21.1K
2	Health Sciences	10	11	11.1K
3	Public Health	9	9	7K
4	Engineering	3	3	148
5	Nursing	1	1	32

Fred Lublin

147

Publications

47.5K

Citations

H-Index

Page 1

	Year	Citations
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria Chris H. Polman, Stephen C. Reingold, Brenda Banwell, Annals of Neurology Mcdonald CriteriaNeurological DisorderMedicineNeuroepidemiologyDiagnostic Criterion	2011	9.7K
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis W. I. McDonald, Alistair Compston, Gilles Edan, Annals of Neurology	2001	6.9K
New Multiple Sclerosis Phenotypic Classification Fred Lublin European Neurology	2014	4.2K
Defining the clinical course of multiple sclerosis Fred Lublin, Stephen C. Reingold Neurology Neurological DisorderPatient SelectionClinical NeurologySurvey ResultsPrimary Care	1996	3.7K
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis Chris H. Polman, Paul O’Connor, Eva Havrdová, New England Journal of Medicine	2006	3.3K
Defining the clinical course of multiple sclerosis Fred Lublin, Stephen C. Reingold, Jeffrey A. Cohen, Neurology Neuroimaging BiomarkersSclerodermaNeurological DiseaseDisease ProgressionMedicine	2014	3K
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis Stephen L. Hauser, Amit Bar‐Or, Gavin Giovannoni, New England Journal of Medicine	2016	1.9K
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis Xavier Montalbán, Stephen L. Hauser, Ludwig Kappos, New England Journal of Medicine	2016	1.8K
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis Richard A. Rudick, William H. Stuart, Peter A. Calabresi, New England Journal of Medicine	2006	1.3K
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial Peter A. Calabresi, Ernst-Wilhelm Radüe, Douglas S. Goodin, The Lancet Neurology Disease ManagementRelapsing-remitting Multiple SclerosisDisease ProgressionNeurological DisorderClinical Trials	2014	815

Page 1